ASBMB Annual Meeting

Focusing on a pivotal axis in chemoresistance

Stephanie Ramadan
March 24, 2024

Chemotherapy is a frontline cancer treatment, but, over time, many cancers become resistant to the effects of chemotherapeutic drugs. Gastric carcinoma, or GC, is no exception and is among the top five causes of cancer-related mortalities worldwide. Chemoresistance occurs in GC via any number or combination of mechanisms, including a reduction in drug uptake or changes in the expression of molecular targets.

Portrait of Marwah Al-Mathkour
Marwah Al-Mathkour

Marwah Al-Mathkour, a postdoctoral fellow at the University of Miami, studies this problem. “I am working with my colleagues to define the signaling pathway that leads to drug resistance in gastric cancer,” she said. “One important player is the CDK1–SOX9 axis.” 

Cyclin-dependent kinase 1, or CDK1, is a critical cell cycle-regulating protein that shows increased tumor expression correlated with poor patient survival. The transcription factor SOX9 is a tumor suppressor in some cancers and an oncogene in others, including gastric cancer. CDK1 can regulate SOX9 expression through microRNA, or miRNA.

Al-Mathkour’s research in Wael El-Rifai’s lab focuses on underlying molecular and functional mechanisms of CDK1 and SOX9 genes in GC chemotherapy resistance. A challenging aspect of this work is trying to define how CDK1 and SOX9 drive this resistance. 

“We are trying different techniques to find the connection, to understand the epigenetic mechanisms that explain the relationship between CDK1 and SOX9,” Al-Mathkour said. “In my work, microRNA is one of the players that contribute to the drug resistance.” 

Researchers have previously reported specific miRNA changes in GC, which Al-Mathkour’s team observed in their data set. When they treated cells with a DNA methyltransferase inhibitor called 5-Aza, they saw upregulation in expression of miR-145, a tumor suppressor with many tumor-specific targets that regulates tumor growth, invasion and metastasis. CDK1 and SOX9 expression increases in multiple cell lines that are resistant to the chemo drug cisplatin; when both proteins are silenced, the cells become sensitive to chemotherapy. 

Al-Mathkour said she wants to find ways to “improve the treatment for patients with resistance to chemotherapy.” One approach is to understand chemoresistance at a mechanistic level. 

Details

Marwah Al-Mathkour will present this research from 5:30 to 6:30 p.m. CDT on Sunday, March 24, at Discover BMB 2024, the American Society for Biochemistry and Molecular Biology annual meeting in San Antonio. Her poster is at Board 324.

Abstract title: CDK1–SOX9 axis contributes to chemotherapy resistance in gastric cancer.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Stephanie Ramadan

Stephanie Ramadan is an assistant professor in human biology at the University of Wisconsin–Green Bay. Her research focuses on protein–protein interactions and novel method development. She is an ASBMB Today volunteer contributor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

How signals shape DNA via gene regulation
Journal News

How signals shape DNA via gene regulation

Aug. 19, 2025

A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent MCP paper.

A game changer in cancer kinase target profiling
Journal News

A game changer in cancer kinase target profiling

Aug. 19, 2025

A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent MCP paper.

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.

Unraveling cancer’s spaghetti proteins
Profile

Unraveling cancer’s spaghetti proteins

Aug. 13, 2025

MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.

How HCMV hijacks host cells — and beyond
Profile

How HCMV hijacks host cells — and beyond

Aug. 12, 2025

Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Understanding the lipid link to gene expression in the nucleus
Profile

Understanding the lipid link to gene expression in the nucleus

Aug. 11, 2025

Ray Blind, an ASBMB Breakthroughs speaker, presented his research on how lipids and sugars in the cell nucleus are involved in signaling and gene expression and how these pathways could be targeted to identify therapeutics for diseases like cancer.